How does hormone therapy treat prostate cancer?
Schmitt B, Bennett C, Seidenfeld J et al. Maximal androgen
blockade for advanced prostate cancer. Cochrane Database of
Systematic Reviews 1999, Issue 2.
Who can have hormone therapy?
Augustovski F, Colantonion L, Pichon Riviere A. Androgen
deprivation treatment (hormonal therapy) for the management of
prostate cancer. Health Technology Assessment 2006, Report ITB
No.30.
Kumar S, Shelley M, Harrison C et al. Neo-adjuvant and adjuvant
hormone therapy for localised and locally advanced prostate cancer.
Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.:
CD006019
National Institute for Health and Clinical Excellence. 2008.
Prostate cancer: diagnosis and treatment. Available at http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11924
What types of hormone therapy are there?
Burns-Cox N, Basketter V, Higgins B et al. Prospective
randomised trial comparing diethylstilboestrol and flutamide in the
treatment of hormone relapsed prostate cancer. International
Journal of Urology 2002; 9(8): 431-434.
What does the treatment involve?
Boccon-Gibod L, Hammerer P, Madersbachert S et al. The role of
intermittent androgen deprivation therapy in prostate cancer. BJU
2007; 100;738-743.
Loblaw DA, Virgo KS, Nam R et al. Initial hormonal management of
androgen-sensitive Metastatic, recurrent, or progressive prostate
cancer - 2006 update of an American Society of Clinical Oncology
practice guideline. Journal of Clinical Oncology 2007; 25(12):
1596-1605.
Schmitt B, Bennett C, Seidenfeld J et al. Maximal androgen
blockade for advanced prostate cancer. Cochrane Database of
Systematic Reviews 1999, Issue 2.
Managing the side effects of hormone therapy
Loss of sex drive and erectile dysfunction
Mottet, Prayer-Galetti, Hammerert Pet al. Optimizing outcomes
and quality of life in the hormonal treatment of prostate cancer.
BJU Int. 2006; 98: 20-27
Mulhall JP. Saving your Sex Life; a guide for men with prostate
cancer.
Potosky AL, Knopf K, Clegg LX et al. Quality-of-Life outcomes
after primary androgen deprivation therapy: results from the
prostate cancer outcomes study. J Clin Oncol 2009;
19(17):3750-3757.
Sharifi N, Gulley JL, Dahut et al. Androgen deprivation for
prostate cancer.JAMA 2005; 294(2):238-244.
Hot flushes
Filshie J, Bolton T, Browne D, Ashley S. Acupuncture and self
acupuncture for long-term treatment of vasomotor symptoms in cancer
patients--audit and treatment algorithm. Acupunture Medicine 2005;
23(4):171-80.
Gerber, G. S., Zagaja, G. P., Ray, P. S. & Rukstalis, D. B.
(2000) Transdermal estrogen in the treatment of hot flushes in men
with prostate cancer. Urology, 55: 97-101.
Hammar M, Frisk J, Grimas O et al. Acupuncture treatment of
vasomotor symptoms in men with Prostatic carcinoma: a pilot study.
J Urol 1999; 161: 853-856.
Harding C, Harris A, Chadwick D. Auricular acupuncture: a novel
treatment for vasomotor symptoms associated with
luteinizing-hormone releasing hormone agonist treatment for
prostate cancer. BJU Int. 2009;103(2):186-90
Higano CS. Side effects of androgen deprivation therapy:
monitoring and minimizing toxicity. Urology 2003; 61(Suppl 2A):
32-38.
Mottet, Prayer-Galetti, Hammerert Pet al. Optimizing outcomes
and quality of life in the hormonal treatment of prostate cancer.
BJU Int. 2006; 98: 20-27
Moyad MA. Complementary/alternative therapies for reducing hot
flashes in prostate cancer patients: reevaluating the existing
indirect data from studies of breast cancer and postmenopausal
women. Urology 2002; 59 (Suppl 4A): 20-33.
Bone thinning
Alibhai SMH, Gogov S, Alllibhai Z. Long-term side effects
of androgen deprivation therapy in men with non-metastatic prostate
cancer: a systematic literature review. Critical reviews in
Oncology/Hematology 60 (2006) 201-215
Drudge-Coates L. Bone health: the effect of androgen deprivation
therapy in porstate cancer patients. International Journal of
Urological Nursing 2007; 1(1): 18-26.
Eastham JA. Bone health in men receiving androgen deprivation
therapy for prostate cancer. J Urol 2007; 177:17-24.
Gomella LG. Contemporary use of hormonal therapy in prostate
cancer: managing complications and addressing quality-of-life
issues. BJU International 2007; 99 Supp.1: 25-29.
Higano CS. Understanding treatments for bone loss and bone
metastases in patients with prostate cancer: a practical review and
guide for the clinician. The Urologic Clinics of North America
2004; 31:331-352.
Moyad MA. Complimentary/alternative therapies for reducing hot
flashes in prostate cancer patients: reevaluating the existing
indirect data from studies of breast cancer and postmenopausal
women. Urology 2002; 59 (Suppl 4a): 20-33
National Osteoporosis Society. Osteoporosis: causes, prevention
and treatment. 2001. Bath: NOS.
Polascik TJ. Bone Health in prostate cancer patients receiving
androgen deprivation therapy: the role of bisphosphonates. Prostate
Cancer and Prostatic Diseases 2008; 11:3-19.
www.drinkaware.co.uk
Breast swelling and tenderness
Di Lorenzo G, Autorino R, Perdona S et al. Management of
gynaecomastia in patients with prostate cancer: a systematic
review. Lancet Oncology 2005; 6: 972-79.
Higano CS. Side effects of androgen deprivation therapy:
monitoring and minimizing toxicity. Urology 2003; 61(Suppl 2A):
32-38.
McLeod DG. Tolerability of nonsteroidal antiandrogens in the
treatment of advanced prostate cancer. Oncologist 1997; 2:
18-27.
Tiredness (fatigue)
Di Lorenzo G, Autorino R, Perdona S et al. Management of
gynaecomastia in patients with prostate cancer: a systematic
review. Lancet Oncology 2005; 6: 972-79.
Higano CS. Side effects of androgen deprivation therapy:
monitoring and minimizing toxicity. Urology 2003; 61(Suppl 2A):
32-38.
National Institute for Health and Clinical Excellence. 2008.
Prostate cancer: diagnosis and treatment. Available at http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11924
Segal RJ, Reid RD, Courneya KS et al. Resistance training in men
receiving androgen deprivation therapy for prostate cancer. Journal
of Clinical Oncology 2003; 21: 1653-1659.
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the
androgen deprivation syndrome in men receiving androgen deprivation
for prostate cancer. Archives of internal medicine 2006; 166(4):
465-71.
Stone P, Hardy J, Huddart R et al. Fatigue in patients with
prostate cancer receiving hormone therapy. European journal of
cancer 2000; 36(9): 1134-41.
Strength and muscle loss
Isbarn H, Boccon-Gibod L, Carroll PR et al. Androgen Deprivation
for the treatment of prostate cancer: Consider both benefits and
risks. Eur Urol. 2008 Oct 14. [Epub ahead of print]
Segal RJ, Reid RD, Courneya KS et al. Resistance training in men
receiving androgen deprivation therapy for prostate cancer. Journal
of Clinical Oncology 2003; 21: 1653-1659.
Memory and concentration
Nelson CJ, Lee JS, Gamboa MC et al. Cognitive effects of hormone
therapy in men with prostate cancer: a review. Cancer
2008;113:1097-106.
Risk of heart disease and diabetes
Hakimian P, Blute M, Kashanian J et al. BJU
2008;102:1509-14.
How will hormone therapy affect how I feel?
Beck AM, Robinson JW, Carlson LE et al. Sexual intimacy in
heterosexual couples after prostate cancer treatment: What we know
and what we still need to learn. Urol Oncol. 2008 Feb 22. [Epub
ahead of print]
Helgason AR., Dickman PW, Adolfsson J et al. Emotional
Isolation: Prevalence and the Effect on Wellbeing Among
50-80-Year-Old Prostate Cancer Patients, Scand J Urol Nephrol 35:
97-101, 2001
Oliffe J. Embodied masculinity and androgen deprivation therapy.
Sociology of Health and Illness 2006; 28(4): 410-432.